Active Metastatic Colorectal Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Metastatic Colorectal Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Metastatic Colorectal Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Metastatic Colorectal Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Metastatic Colorectal Cancer Clinical Trial FAQ

What biomarker tests should I have before looking for a metastatic colorectal cancer trial?

All patients with mCRC should have: RAS (KRAS/NRAS) and BRAF V600E mutation testing, MSI/MMR testing, HER2 amplification testing (IHC/FISH), NTRK fusion testing, and POLE/POLD1 mutation testing. These results determine eligibility for most targeted therapy and immunotherapy trials. Comprehensive NGS panel testing is preferred because it captures all these markers simultaneously.

Are there mCRC trials for patients who have had multiple prior lines of chemotherapy?

Yes. Several later-line options are active: trifluridine/tipiracil (TAS-102) combinations, regorafenib combinations, KRAS G12C inhibitors (adagrasib, sotorasib) for KRAS G12C-mutated mCRC (about 3–4% of cases), BRAF V600E-targeted combinations (encorafenib + cetuximab), and novel agents. Trialify lets you filter by number of prior lines so you see trials appropriate for your current situation.

Does MSI-H status help metastatic colorectal cancer patients access trials?

Yes, significantly. MSI-H/dMMR mCRC represents about 4–5% of metastatic cases and is uniquely responsive to checkpoint immunotherapy. Pembrolizumab is FDA-approved as first-line therapy for MSI-H mCRC. Trials are testing pembrolizumab combinations, novel immunotherapy doublets, and strategies for MSI-H patients who progress on PD-1 therapy. MSI-H status is now tested routinely on all CRC tumor specimens.

Can mCRC patients with liver metastases join clinical trials?

Liver metastases are present in the majority of mCRC patients and generally do not exclude you from trials. However, some trials require adequate liver function (ALT/AST and bilirubin within specified limits) or exclude patients with more than a certain number of liver lesions. Hepatic artery infusion (HAI) pump trials are specifically designed for patients with liver-limited disease.

Are there mCRC trials based on HER2 amplification?

Yes. HER2 amplification occurs in 2–3% of mCRC, more commonly in RAS wild-type tumors. FDA-approved regimens include fam-trastuzumab deruxtecan (T-DXd / Enhertu) for HER2-positive mCRC, and tucatinib + trastuzumab + capecitabine is being studied. Trials are expanding HER2-targeted options for mCRC. HER2 testing should now be included in standard mCRC molecular profiling.

Explore Other Cancer Trial Guides

• Colorectal Cancer — Colorectal cancer trials are evaluating immunotherapy for MSI-H tumors, KRAS and BRAF targeted therapies, and novel combinations for metastatic disease. Many trials enroll both colon and rectal cancer patients.
• Pancreatic Cancer — Pancreatic cancer trials are at the forefront of KRAS inhibitor research, mRNA vaccines, and combination immunotherapy. Participating in a trial may give access to treatments not yet available to the general public.
• Liver Cancer — Liver cancer trials are studying checkpoint inhibitor combinations, locoregional treatments (TACE, ablation), and novel targeted agents for hepatocellular carcinoma across all disease stages.
• KRAS-Mutated Lung Cancer — KRAS mutations are the most common oncogenic driver in NSCLC, found in approximately 25–30% of adenocarcinomas. Sotorasib and adagrasib are approved for KRAS G12C, and next-generation KRAS inhibitors targeting G12D, G12V, and pan-KRAS are in active clinical trials.